Ignite Creation Date:
2024-05-06 @ 5:11 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05227950
Status:
UNKNOWN
Last Update Posted:
2022-02-08
First Post:
2022-01-24
Brief Title:
Cell-free DNA Quantification for Predictive Marker of Palliative Chemotherapy
Sponsor:
Pusan National University Yangsan Hospital
Organization:
Pusan National University Yangsan Hospital
Study Overview
Official Title:
Usefulness of Cell-free DNA Quantification With Fluorescent Assay in Response Evaluation of Palliative Chemotherapy
Status:
UNKNOWN
Status Verified Date:
2022-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is design to address as follows
1 correlation between fluorescence-based CFD measurements and tumor burden primary tumor size number of metastatic sites
2 fluorescence-based CFD measurements and changes are related to tumor response Based on the results of this study the role of fluorescence-based CFD as a predictive biomarker for palliative chemotherapy is to be confirmed
1 correlation between fluorescence-based CFD measurements and tumor burden primary tumor size number of metastatic sites
2 fluorescence-based CFD measurements and changes are related to tumor response Based on the results of this study the role of fluorescence-based CFD as a predictive biomarker for palliative chemotherapy is to be confirmed
Detailed Description:
It is important to check the response to chemotherapy Currently it is mostly evaluated as a radiologic response or rarely the change of tumor markers
In the case of radiologic response tests at intervals of 6-8 weeks there are cases where the economic burden and radiation exposure risk additionally evaluation lesion is lack in a few case Except for prostate cancer and ovarian cancer the majority of carcinomas do not have cancer markers for assessing treatment response Therefore there is a need for biomarkers that can predict the response of anticancer treatment
In many studies it has been reported that various types of circulating cell free DNA CFD are increased in various cancer types
Recently a fluorescence based CFD method that can directly measure nucleic acids without a DNA extraction process has been developed which makes testing simpler and more economical and can be conveniently applied to cancer diagnosis and treatment response
This study is plan to evaluate the relationship between fluorescence-based CFD and treatment response in patients starting palliative chemotherapy and check whether it can serve as a response evaluation for palliative chemotherapy
In the case of radiologic response tests at intervals of 6-8 weeks there are cases where the economic burden and radiation exposure risk additionally evaluation lesion is lack in a few case Except for prostate cancer and ovarian cancer the majority of carcinomas do not have cancer markers for assessing treatment response Therefore there is a need for biomarkers that can predict the response of anticancer treatment
In many studies it has been reported that various types of circulating cell free DNA CFD are increased in various cancer types
Recently a fluorescence based CFD method that can directly measure nucleic acids without a DNA extraction process has been developed which makes testing simpler and more economical and can be conveniently applied to cancer diagnosis and treatment response
This study is plan to evaluate the relationship between fluorescence-based CFD and treatment response in patients starting palliative chemotherapy and check whether it can serve as a response evaluation for palliative chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None